{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:09:44Z","timestamp":1780538984715,"version":"3.54.1"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>New available drugs allow better control of systemic symptoms associated with myelofibrosis (MF) and splenomegaly but they do not modify the natural history of progressive and poor prognosis disease. Thus, hematopoietic stem cell transplantation (HSCT) is still considered the only available curative treatment for patients with MF. Despite the increasing number of procedures worldwide in recent years, HSCT for MF patients remains challenging. An increasingly complex network of the patient, disease, and transplant-related factors should be considered to understand the need for and the benefits of the procedure. Unfortunately, prospective trials are often lacking in this setting, making an evidence-based decision process particularly arduous. In the present review, we will analyze the main controversial points of allogeneic transplantation in MF, that is, the development of more sophisticated models for the identification of eligible patients; the need for tools offering a more precise definition of expected outcomes combining comorbidity assessment and factors related to the procedure; the decision-making process about the best transplantation time; the evaluation of the most appropriate platform for curative treatment; the impact of splenomegaly; and splenectomy on outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2024.1396435","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:38:03Z","timestamp":1718858283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Myelofibrosis and allogeneic transplantation: critical points and challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Paola","family":"Ranalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Guardalupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Santarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cant\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Di Ianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11864-020-00734-y","article-title":"Management of myelofibrosis: from diagnosis to new target therapies","volume":"21","author":"Iurlo","year":"2020","journal-title":"Curr Treat Opt Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kroger","year":"2015","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem\u2013cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative\u00a0Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume-title":"J Natl Compr Canc Netw.","author":"Gerds","year":"2022"},{"key":"B8","article-title":"Primary Myelofibrosis: 2023 update on diagnosis, risk-stratification and managment","volume-title":"Am J Hematol","author":"Tefferi","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-03-900860","article-title":"Stem cell transplant in MF: it's time to personalize","volume":"133","author":"Passamonti","year":"2019","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26349","article-title":"2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management","volume":"96","author":"Ali","year":"2021","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000203191.99447.98","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"13","author":"Barosi","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1056\/NEJM200008313430913","article-title":"Myelofibrosis with myeloid metaplasia","volume":"343","author":"Guardiola","year":"2000","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094284","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26279","article-title":"Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic Malignancies working party of EBMT and the Spanish Myelofibrosis Registry","volume":"96","author":"Hernandez\u2013Boluda","year":"2021","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08582.x","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60\u201378 years of age","volume":"153","author":"Samuelson","year":"2011","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13294","article-title":"Allogeneic stem cell transplantation for myelofibrosis patients aged >\/=65 years","volume":"103","author":"Daghia","year":"2019","journal-title":"Eur J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG\u2013MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo\u2013Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kroger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL\u2013mutated or triple\u2013negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1\u2013like versus type 2\/type 2\u2013like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation\u2013enhanced international prognostic score system for transplantation\u2013age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: mutation and karyotype\u2013enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":". J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based\u00a0on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18526","article-title":"Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment","volume":"200","author":"Iurlo","year":"2023","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.149013","article-title":"Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera\/essential thrombocytosis myelofibrosis","volume":"101","author":"Gowin","year":"2016","journal-title":"Haematologica"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.169","article-title":"A clinical\u2013molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajh.25335","article-title":"Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients","volume":"94","author":"Kuykendall","year":"2019","journal-title":"Am J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26548","article-title":"Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis","volume":"97","author":"Mannelli","year":"2022","journal-title":"Am J Hematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"key":"B49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-022-00713-6","article-title":"Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis","volume":"12","author":"Coltro","year":"2022","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2203318","article-title":"Cytopenic myelofibrosis: prevalence, relevance, and treatment","volume":"24","author":"Vachhani","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT\u2013I and COMFORT\u2013II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.016","article-title":"Hematopoietic cell transplantation for myelofibrosis: the dynamic international prognostic scoring system plus risk predicts post\u2013transplant outcomes","volume":"24","author":"Samuelson Bannow","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.061168","article-title":"Dynamic International Prognostic Scoring System scores, pre\u2013transplant therapy and chronic graft\u2013versus\u2013host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Ditschkowski","year":"2012","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced\u2013intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br J Haematol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.024","article-title":"Comparison of dynamic international prognostic scoring system and MYelofibrosis SECondary to PV and ET prognostic model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27262","article-title":"Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT","volume":"99","author":"Polverelli","year":"2024","journal-title":"Am J Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)\u2013specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced\u2013intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical\u2013molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.07.022","article-title":"Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the myelofibrosis transplant scoring system (MTSS) and development of a new prognostic model","volume":"26","author":"Hernandez\u2013Boluda","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019630","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome\u2013negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"B65","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan\u2013 or thiotepa\u2013based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post\u2013transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post\u2013transplantation cyclophosphamide\u2013based graft\u2013 versus\u2013host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.276","article-title":"Retrospective study of allogeneic haematopoietic stem\u2013cell transplantation for myelofibrosis","volume":"46","author":"Lissandre","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07010.x","article-title":"Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation","volume":"141","author":"Ciurea","year":"2008","journal-title":"Br J Haematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajh.26020","article-title":"Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic Malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.249","article-title":"Effects of spleen status on early outcomes after hematopoietic cell transplantation","volume":"48","author":"Akpek","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/bcj.2011.36","article-title":"How I treat splenomegaly in myelofibrosis","volume":"1","author":"Cervantes","year":"2011","journal-title":"Blood Cancer J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymph"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24881","article-title":"Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90686-0","article-title":"Splenectomy before bone marrow transplantation in chronic granulocytic leukaemia","volume":"327","author":"MiguelA. Sanz","year":"1986","journal-title":"Lancet"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26034","article-title":"Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study","volume":"96","author":"Bossard","year":"2021","journal-title":"Am J Hematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double\u2013blind, placebo\u2013controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2\u2013year follow\u2013up of COMFORT\u2013I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.015","article-title":"Splenectomy in myelofibrosis: indications, efficacy, and complications","volume":"20","author":"Malato","year":"2020","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27252","article-title":"Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00018-7","article-title":"Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients","volume":"24","author":"Bouabdallah","year":"2000","journal-title":"Leuk Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea","volume":"58","author":"Wagner","year":"1986","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.01.018","article-title":"Optimal timing of allogeneic stem cell transplantation for primary myelofibrosis","volume":"28","author":"Cipkar","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.543","article-title":"Myelofibrosis: to transplant or not to transplant","volume":"2016","author":"Devlin","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded\u2013access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymph"},{"key":"B91","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single\u2013cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single\u2013institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13330","article-title":"Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population\u2013based cohort study in Sweden and Norway","volume":"103","author":"Schain","year":"2019","journal-title":"Eur J Haematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41409-023-02146-6","article-title":"Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study","volume":"59","author":"Maze","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","first-page":"S356","DOI":"10.1016\/S2152-2650(21)01822-X","article-title":"MPN\u2013164: overall survival (OS) and progression\u2013free survival (PFS) in patients treated with fedratinib as first\u2013line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): results from the JAKARTA and JAKARTA2 trials","volume":"21","author":"Claire Harrison","year":"2021","journal-title":"Myeloproliferative Neoplasms"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135872","article-title":"Myeloproliferative syndromes: clinical robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high risk myelofibrosis patients","volume":"136","author":"Srdan Verstovsek","year":"2020","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0683-1","article-title":"The role of allogeneic stem\u2013cell transplant in myelofibrosis in the era of JAK inhibitors: a case\u2013based review","volume":"55","author":"Tiribelli","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206151","article-title":"State\u2013of\u2013the\u2013art review: allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced\u2013intensity conditioning for hematopoietic cell transplantation for myelofibrosis: myeloproliferative disorders research consortium 114 study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2040620720906002","DOI":"10.1177\/2040620720906002","article-title":"Allogeneic hematopoietic stem\u2013cell transplantation for myelofibrosis","volume":"11","author":"Zhang","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01252-7","article-title":"Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM\u2013TC and FIM groups","volume":"56","author":"Robin","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.295","article-title":"Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem\u2013cell transplantation for myeloproliferative neoplasms","volume":"51","author":"Hanif","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13099","article-title":"Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"101","author":"Shahnaz Syed Abd Kadir","year":"2018","journal-title":"Eur J Haematol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000279","article-title":"Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how","volume":"2021","author":"England","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"key":"B111","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced\u2013intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.011","article-title":"Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis","volume":"20","author":"Robin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.028","article-title":"Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors","volume":"22","author":"Bregante","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B114","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-02278-5","volume-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","author":"Carreras","year":"2019"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hernandez\u2013Boluda","year":"2021","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.013","article-title":"Outcomes of salvage haploidentical transplant with post\u2013transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the francophone society of bone marrow transplantation and cellular therapy","volume":"25","author":"Prata","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15407","article-title":"Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT","volume":"182","author":"McLornan","year":"2018","journal-title":"Br J Haematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.09.006","article-title":"Incidence and outcome of late relapse after allogeneic stem cell transplantation for myelofibrosis","volume":"26","author":"Atagunduz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02094-1","article-title":"Allogeneic hematopoietic cell transplantation in patients with CALR\u2013mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT","volume":"58","author":"Hernandez\u2013Boluda","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK\u2013inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kroger","year":"2021","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01305-x","article-title":"Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis","volume":"56","author":"McLornan","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.08.024","article-title":"Australasian trends in allogeneic stem cell transplantation for myelofibrosis in the molecular era: A retrospective analysis from the australasian bone marrow transplant recipient registry","volume":"26","author":"Lwin","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000921","article-title":"Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Hemasphere"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01271-4","article-title":"Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT","volume":"56","author":"Nabergoj","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant\u2013eligible patients with myelofibrosis","volume":"142","author":"Kroger","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1396435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:38:09Z","timestamp":1718858289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1396435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":127,"alternative-id":["10.3389\/fonc.2024.1396435"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1396435","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"article-number":"1396435"}}